AEGiS-CATIE: TreatmentUpdate: Indinavir with DMP 266

TreatmentUpdate: Indinavir with DMP 266

TreatmentUpdate 76. 9(2): 6; March, 1997
Sean Hosein

This article is based on information presented at the 4th Conference on Retroviruses and Opportunistic Infections in Washington, DC, January 22-26, 1997.

Study details

DMP 266 is a new drug that, like AZT, affects the HIV enzyme RT (reverse transcriptase). The drug is not related to AZT, but acts in a similar way to the drugs delavirdine and nevirapine. Doctors reported results on 30 subjects (4 female, 26 male) with an average CD4+ count of 240 cells and a viral load of 100,000 copies. No subject was supposed to have used protease inhibitors, delavirdine, nevirapine or loviride before entering this study. Subjects received indinavir 2.4 grams/day for 2 weeks and then either DMP 266, 200 mg/day or fake DMP 266. Since DMP 266 reduces levels of indinavir in the blood by 35%, the dose of indinavir used was increased to 3 grams/day starting at the 8th week of the study.

Results

After 2 weeks of indinavir the average viral load fell to 1/25th its pre-study level. When DMP 266 was added to indinavir, the viral load fell to 1/250th its pre-study value and remained low for at least 6 months. The CD4+ count increased by 100 cells. Eight subjects reported skin rash; others had pain due to kidney stones which cleared while they continued to use indinavir. Levels of liver enzymes in the blood rose. A study of DMP 266 with indinavir is planned to take place at several sites in Canada later this year.

REFERENCES:

1. Gridler S and the DuPont Merck Study Group. A double-blind pilot study to evaluate the antiretroviral activity, tolerability of DMP 266 in combination with indinavir. Oral presentation LB2.

970320
CATE7609

ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users l This article first appeard in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1997 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca

Disclaimer: The editors have taken all such care as they consider reasonable in preparing this database, but they cannot be held responsible for any inaccuracies or mis-statements of fact contained herein. Inclusion in this database of any information on any treatment, therapy, or clinical trial in no way represents an endorsement of that treatment, therapy, or trial by ÆGiS or any of its sponsors. This data should always be used in conjunction with professional medical advice.
©1997. ÆGiS.